ILA to ILD Progression Features
Progression from interstitial lung abnormality (ILA) to interstitial lung disease (ILD) is defined by at least two of three criteria occurring within one year: worsening respiratory symptoms, physiologic decline (FVC >5% or DLCO >10% predicted), and radiologic progression on HRCT. 1
Radiologic Features Indicating Progression
The 2022 ATS/ERS/JRS/ALAT guideline establishes specific HRCT criteria for radiologic progression 1:
High-Risk Radiologic Patterns
- Increased extent or severity of traction bronchiectasis and bronchiolectasis (strongest independent predictor of mortality in IPF) 1
- New ground-glass opacity with traction bronchiectasis 1
- New fine reticulation 1
- Increased extent or coarseness of reticular abnormality 1
- New or increased honeycombing 1, 2
- Increased lobar volume loss 1
Pattern Evolution
In non-IPF ILDs, progression patterns vary and may include 1:
- Evolution of ground-glass abnormality to reticular abnormality
- Evolution of reticular abnormality to honeycombing
- Increase in traction bronchiectasis/bronchiolectasis
Additional Radiologic Risk Factors
Recent evidence identifies 3:
- Bronchial wall thickening (OR 2.61,95% CI: 1.08-6.23)
- Mosaic attenuation (OR 2.51,95% CI: 1.02-6.17)
Subpleural fibrotic ILA patterns carry significantly higher progression risk than non-subpleural or subpleural nonfibrotic patterns 4, 5. The extent of honeycombing independently predicts ILD progression (adjusted OR 1.53,95% CI 1.17-2.01) 2.
Physiologic Features Indicating Progression
Pulmonary Function Criteria
Physiologic evidence of disease progression requires either 1:
- Absolute decline in FVC >5% predicted within 1 year of follow-up
- Absolute decline in DLCO (corrected for Hb) >10% predicted within 1 year of follow-up
Important Caveat
Worsening respiratory symptoms and DLCO decline have lower specificity for progression compared to FVC decline and HRCT changes 1. Alternative explanations (infection, heart failure, pulmonary hypertension) must be rigorously excluded before attributing these changes to ILD progression.
Longitudinal Trajectory
Greater cumulative decline in FVC from early adulthood strongly predicts ILA development—each 10% absolute decline in ppFVC associates with more than twice the odds of ILA (adjusted OR 2.21,95% CI 1.47-3.31) 6. This suggests physiologic impairments precede radiologic evidence.
Clinical Features Indicating Progression
Symptom Assessment
Emerging respiratory symptoms are a significant predictor of clinically significant ILD (OR 5.56,95% CI 1.28-24.21) 5. Specifically assess for:
The severity of self-rated dyspnea correlates with ILA extent, and progressive ILAs correlate with progressive dyspnea during follow-up 7.
Risk Factors for Progression
Independent risk factors identified include 8:
- Older age
- Ever-smoking status
- Higher white blood cell counts
- Higher erythrocyte sedimentation rates
- Higher rheumatoid factors
Monitoring Algorithm
Follow-Up Timing
Patients should be evaluated every 3-6 months or more frequently for disease progression 1. The 2025 Italian expert consensus recommends 24-month follow-up HRCT for PPF assessment 9.
Structured Evaluation
At each visit, assess:
- Respiratory symptoms (cough, dyspnea) 7
- Pulmonary function testing (FVC, TLC, DLCO) 7
- HRCT imaging when clinically indicated or at structured intervals 9
Progression Definition
Progressive ILA requires radiologic progression on follow-up CT (OR 4.07,95% CI 1.00-16.54) 5. Approximately 23% of screening populations with ILAs develop clinically significant ILD over mean 8.7-year follow-up 5, with 83.3% of baseline ILA patients showing radiologic progression 8.
Critical Distinction: ILA vs PPF
PPF specifically applies to patients with established ILD (not ILA) who demonstrate progression 1. The criteria are identical (2 of 3: symptoms, physiology, radiology within one year), but PPF requires pre-existing radiologic evidence of pulmonary fibrosis beyond the ILA threshold.
Mortality Impact
Both ILA and equivocal ILA at follow-up significantly associate with all-cause mortality (adjusted HR for equivocal ILA 3.73, for ILA 4.01), but progressive ILA further increases mortality risk (adjusted HR 3.92) compared to non-progressive or no ILA 8. Pulmonary vessel volume percentage independently predicts mortality (adjusted HR 1.21,95% CI 1.094-1.354), particularly in upper lung zones 2.